June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Dropless Cataract Surgery with Pars Plana Intravitreal Trimoxi Use - An Outcomes Analysis
Author Affiliations & Notes
  • Bronson LeClair
    School of Medicine, Loma Linda University, Loma Linda, California, United States
  • Michael E Rauser
    Loma Linda Eye Institue , Loma Linda, California, United States
  • Eden Yoon
    Loma Linda Eye Institue , Loma Linda, California, United States
  • Footnotes
    Commercial Relationships   Bronson LeClair, None; Michael Rauser, None; Eden Yoon, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1827. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bronson LeClair, Michael E Rauser, Eden Yoon; Dropless Cataract Surgery with Pars Plana Intravitreal Trimoxi Use - An Outcomes Analysis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1827.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Topical NSAIDS, corticosteroids, and antibiotics have been the mainstay for prophylaxis and treatment following cataract surgery to reduce inflammation and prevent post-op infectious endophthalmitis. Our study compares the outcomes of intraoperative pars plana intravitreal injection of Trimoxi + topical NSAID (“Dropless”) versus traditional eyedrop usage after cataract surgery. Our hypothesis was that the pars plana intravitreal injection of Trimoxi + topical NASAID is a non-inferior treatment method to standard eyedrop therapy for cataract surgery.

Methods : This retrospective cohort study analyzed a total of 530 patients. 263 patients received standard therapy (4 four-week taper of antibiotic, NSAID and steroid eye drops) ; 267 patients received 0.2 mL of Trimoxi (Triamcinolone acetate – 15mg/mL ; Moxifloxacin – 1mg/mL) injected into the vitreous via the pars plana during cataract surgery + postop topical NSAID. Anterior chamber inflammation, corneal edema, and IOP were measured at 1 day, 1 week and 1 month postop. Other complications and modifications to the planned postop regimen were also noted.

Results : A binary logistic regression shows no statistically significant differences between the two treatment groups across the three time points in all measured outcomes. Regarding anterior chamber inflammation (OR=0.997), no significant differences were detected between the treatment groups (p=0.9892). In the Dropless group, 22 eyes were given additional steroid drops postoperatively. In the standard eye drop regimen group 3 eyes required altered therapy (restart or increase the steroid/NSAID). A slight increase in the odds of corneal edema in the dropless group (OR=1.42) was found, although the p-value is not regarded as statistically significant (p=0.0815). Regarding postop IOP, there are decreased odds of elevated pressure in the dropless group (OR=0.651), but again there is no significant differences detected between treatment groups (p=0.1208).

Conclusions : Intravitreal Trimoxi during cataract surgery + postop NSAID use appears non-inferior to traditional postop eyedrop use after cataract surgery. However, more patients in the dropless group required an alteration in the planned eye drop regimen versus the traditional group.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.